for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
PharmAsia News  
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [13 journals]
  • Taiwan Shifting NHI Costs Through Rx Deregulation
    • Abstract: Health authorities in Taiwan are planning to shift a group of prescription-only drugs to less restricted sale as part of a broader effort to foster "responsible self-medication" and save costs in the national insurance scheme.
      PubDate: Wed, 21 Jan 2015 19:05:01 -050
  • Roundup: Three Chinese Deals To Put On Your Radar
    • Abstract: The New Year may have just kicked off, but in China it has already seen two acquisitions, one fundraising and over a hundred million dollars in transactions.
      PubDate: Wed, 21 Jan 2015 18:55:05 -050
  • Mylan’s Famy Care Affair May Culminate In Buyout
    • Abstract: Mylan is seen as an aggressive buyer of businesses in India. After signing a series of acquisitions that bolstered its manufacturing capabilities, the company is now moving closer to a deal with Famy Care, its long-time partner for oral contraceptives.
      PubDate: Wed, 21 Jan 2015 18:55:01 -050
  • Emerging Markets On Executives’ Minds At JPM15
    • Abstract: Several top executives from major multinationals made comments on emerging market strategies at the JP Morgan Healthcare Conference in San Francisco Jan. 12-15 that piqued the interest of PharmAsia News. Among them, GSK said it was looking for a broad product portfolio, Lilly noted it had doubled its sales in China and Becton Dickinson highlighted the need to develop targeted products.
      PubDate: Wed, 21 Jan 2015 03:00:01 -050
  • EXCLUSIVE: Turkish Industry Pleads For Value-Based Approach
    • Abstract: At the beginning of a new year, the Turkish Association of Research Based Pharmaceutical Companies (AIFD) is asking the government to adopt a “value based” approach to healthcare instead of focusing on costs and prices. In an exclusive interview, AIFD Secretary General and Chief Operating Officer Osman Kara highlights the potential of innovative pharmaceuticals and said that with a transparent and sustainable system, the industry could help Turkey to become a regional hub for healthcare.
      PubDate: Wed, 21 Jan 2015 01:30:01 -050
  • China County Level Hospitals Present New Opportunities
    • Abstract: The majority of China’s healthcare resources have long been controlled by top-level hospitals in urban areas. These major facilities, categorized as “san jia yi yuan” (三甲医院), have naturally been the priority target for foreign drug and medical devices manufacturers wanting to score sales in China.
      PubDate: Tue, 20 Jan 2015 18:55:00 -050
  • BMS Slims Down India Ops Under Global Plans
    • Abstract: Following news of a downsizing exercise in China as reported by PharmAsia News in December, Bristol-Myers Squibb has trimmed staff across the board in India, as part of a global restructuring process.
      PubDate: Tue, 20 Jan 2015 18:50:01 -050
  • New Japan Partner For Solasia’s Key Oncology Project
    • Abstract: The Japanese venture Solasia has signed a product licensing and investment agreement with major firm Meiji Seika that will support the planned commercialization of its major oncology prospect.
      PubDate: Tue, 20 Jan 2015 00:25:00 -050
  • Lilly/BI Gain Japan Approval For First Lantus Biosimilar
    • Abstract: Lilly and Boehringer Ingelheim have confirmed that they have received regulatory approval in Japan for their insulin glargine product as the first biosimilar version of Sanofi's Lantus, the first such local competition for the branded basal insulin analog.
      PubDate: Mon, 19 Jan 2015 18:30:05 -050
  • Have Global Firms Gained From India’s Price Caps'
    • Abstract: After a prolonged period of shrinking market share and dimming prospects, global drug makers are seeing a rebound in India, with some even outclassing their local rivals in highly prescribed categories. If the trend continues, drug makers may be encouraged to pump in further investments, say experts.
      PubDate: Mon, 19 Jan 2015 18:30:00 -050
  • Novartis Ditches Two Products In China To Focus On New Launches
    • Abstract: Amid regulatory approval delays and commercial uncertainties, multinationals are reviewing and adjusting local product strategies to adapt to a new norm. As part of life cycle management, Novartis has just out-licensed two established drugs in line with its intention to focus on innovative products.
      PubDate: Mon, 19 Jan 2015 18:20:00 -050
  • Piramal Bags Coldstream For Edge In Antibody-Drug Conjugates
    • Abstract: Piramal has acquired Coldstream of the U.S. in a move that helps the Indian company engage with cutting edge biotech drug makers and offer full spectrum services through proprietary capabilities in antibody-drug conjugates (ADCs).
      PubDate: Sun, 18 Jan 2015 20:50:00 -050
  • JPM15: Abbott Eyes Emerging Markets Only For Branded Generics Biz
    • Abstract: Just in case the sight of Abbott divesting its branded generics businesses in developed markets to Mylan was not a clear enough signal of the company’s intention to focus solely on emerging markets, Michael J. Warmuth , the EVP with responsibility for the business, took the opportunity to spell it out at the recent JP Morgan Healthcare conference.
      PubDate: Sun, 18 Jan 2015 19:00:01 -050
  • Emerging Markets Regulatory Tracker: China Revises Device GMP Rules
    • Abstract: China has revised good manufacturing practice regulations for medical devices, imposing a number of new requirements on manufacturers.
      PubDate: Sun, 18 Jan 2015 18:55:01 -050
  • Gilead Still Has Options After Indian Sovaldi Patent Refusal
    • Abstract: All is not lost for Gilead in its efforts to obtain a patent for Sovaldi in India. The company played down the latest rejection of its claims, noting that the main patent covering sofosbuvir is still pending with the Indian authorities.
      PubDate: Fri, 16 Jan 2015 02:05:01 -050
  • Fosun’s $800m R&D Investment: Evolution Or Revolution'
    • Abstract: Shanghai Fosun Pharmaceutical’s new planned investment in R&D is significant, although it is likely to result in incremental but profitable returns rather than novel blockbuster drugs.
      PubDate: Thu, 15 Jan 2015 20:10:01 -050
  • Regulator Sets Tough Tone At Indian Manufacturers’ Meeting
    • Abstract: If the annual meeting of the Indian Drug Manufacturers' Association (IDMA) is anything to go by, then the drug regulatory regime in the country appears set for a significant makeover.
      PubDate: Thu, 15 Jan 2015 19:20:01 -050
  • Allegro Inks Second Asian Alliance For Luminate
    • Abstract: Allegro has secured a second Asian partner for its novel integrin peptide therapy for ophthalmic disorders, linking with Hanmi for the Korean and Chinese markets.
      PubDate: Thu, 15 Jan 2015 18:55:05 -050
  • Emerging Markets Regulatory Tracker: China Approves Sabin Vaccine
    • Abstract: China has approved a domestically developed Sabin vaccine for polio.
      PubDate: Thu, 15 Jan 2015 18:55:01 -050
  • JPM15: Medtronic Eyes $5bn-plus Opportunity In Emerging Markets
    • Abstract: Omar Ishrak, chairman and CEO of medtech giant Medtronic, believes he can boost his company’s annual revenues by $5 billion by selling existing products at existing prices to those people who can afford them in emerging markets. However, the strategy is not as straight forward as it first sounds.
      PubDate: Thu, 15 Jan 2015 01:05:01 -050
  • Shock Indian Patent Refusal For Gilead’s Sovaldi
    • Abstract: Close to a decade after Gilead first filed its application for grant of a local patent for its blockbuster hepatitis C drug Sovaldi, the Indian Patent Office has refused the petition, citing Section 3(d) of the Patent Act.
      PubDate: Wed, 14 Jan 2015 18:40:00 -050
  • Key China Regulatory Agenda For January
    • Abstract: Further lowering barriers for physicians to practice in multiple locations and potentially allowing prescription drug online sales are among the major topics on the Chinese regulator’s agenda for January.
      PubDate: Wed, 14 Jan 2015 18:30:01 -050
  • Takeda Authorizes Colcrys Generic As Litigation Drags On
    • Abstract: Takeda has granted the U.S. form Prasco Laboratories rights to an authorized generic version of its gout drug Colcrys (colchicine), in an apparent move to stave off other generic challengers and make the drug more widely available.
      PubDate: Wed, 14 Jan 2015 18:30:00 -050
  • NextCODE Buy Boosts WuXi’s Genomics Expertise
    • Abstract: WuXi PharmaTech has acquired the genomic analysis company NextCODE Health for $65 million in cash. The Shanghai-based R&D technology firm plans to merge the NextCODE Health business into its own genome center, creating a new company to be known as WuXi NextCODE Genomics.
      PubDate: Tue, 13 Jan 2015 20:25:00 -050
  • India’s Cadila Takes Saroglitazar Into NASH
    • Abstract: The Indian drug maker Zydus Cadila is working to treat NASH, the serious fatty liver disease, with its established diabetes dyslipidemia compound saroglitazar, which gained approval in India in 2013.
      PubDate: Tue, 13 Jan 2015 19:35:00 -050
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014